Posters

T-ASLA a novel approach of surface ablation for myopia and CXL

Poster Details

First Author: I.Aslanides GREECE

Co Author(s):    S. Arba Mosquera   V. Selimis           

Abstract Details

Purpose:

We report our experience with transepithelial ASLA (All Surface Laser Ablation) with the use of Smart Pulse Technology (SPT).

Setting:

Emmetropia Mediterranean Eye Institute, Heraklion, Crete, Greece

Methods:

Thirty-two (32) eyes of seventeen (17) myopic patients with a range of -0.5 to -9.25 Dioptres (D) (mean -3,69D) underwent ASLA (All Surface Laser Ablation) treatment using the Amaris 750S laser platform (SCHWIND eye-tech-solutions,Kleinhostheim Germany) with Smart Pulse Technology (SPT).Among them four (4) eyes from three (3) patients also had CXL treatment for prophylactic reasons.All eyes received a matrix regenerating agent (RGTA) CACICOL (Thea,France) immediately.The presence of postoperative epithelial defect,UDVA and CDVA were assessed at 24 hours, 48 hours and 1 week.The data were compared with a previous consecutive group of 40 eyes treated without smart pulse technology and CACICOL.

Results:

The group of eyes with SPT had better UDVA and CDVA at all times and 1 week after the treatment 74% of eyes achieved an UDVA of 20/25 or better versus 20% in the group without SPT. In terms of safety no eye lost more than 1 line of Snellen acuity. The predictability was similar in both groups with 100% eyes +/-1 D after 1 month.

Conclusions:

The use of SPT seems to offer a faster visual recovery even if an epithelial defect is present compared to transepithelial ASLA treatments without SPT.This is likely due to the smoother stromal bed after the treatment.There was no adverse event, and no incidences of inflammation, delayed healing or haze. The use of SPT in our series is a safe and effective addition on the surface laser ablation as. The combined use of SPT with RGTAs has the potential to offer both faster recovery of the visual function and faster epithelial healing with reduced pain even in patients that had CXL. FINANCIAL DISCLOUSRE: One or more of the authors is employed by a for-profit company with an interest in the subject of the presentation, One or more of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented